Kaken Pharmaceutical Co., Ltd. (TYO:4521)

Japan flag Japan · Delayed Price · Currency is JPY
4,786.00
-37.00 (-0.77%)
Mar 13, 2025, 3:30 PM JST
35.05%
Market Cap 180.89B
Revenue (ttm) 93.35B
Net Income (ttm) 20.53B
Shares Out 37.87M
EPS (ttm) 541.97
PE Ratio 8.81
Forward PE 23.46
Dividend 150.00 (3.13%)
Ex-Dividend Date Mar 28, 2025
Volume 203,900
Average Volume 275,530
Open 4,790.00
Previous Close 4,823.00
Day's Range 4,738.00 - 4,795.00
52-Week Range 3,367.00 - 4,901.00
Beta 0.16
RSI 68.61
Earnings Date May 9, 2025

About Kaken Pharmaceutical

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surger... [Read more]

Sector Healthcare
Founded 1917
Employees 1,135
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4521
Full Company Profile

Financial Performance

In 2023, Kaken Pharmaceutical's revenue was 72.04 billion, a decrease of -1.29% compared to the previous year's 72.98 billion. Earnings were 8.03 billion, an increase of 47.52%.

Financial Statements

News

Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Topline Data from CAHmelia-204 Study of Tildacerfont in Adult Congenital Adrenal Hyperplasia (CAH) Anticipated in December 2024 Topline Data from CAHptain-205 Study of Tildacerfont in Adult and Pediat...

4 months ago - Benzinga